Biopharma Cred. Regulatory News (BPCR)

 This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014 

BIOPHARMA CREDIT PLC

(THE "COMPANY")

SPECIAL DIVIDEND DECLARATION AND NET ASSET VALUES

Special Dividend of 4.50 cents Declared, 6.25 cents Total Payable this Quarter

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to announce the following:

DIVIDEND DECLARATION - Ordinary and Special Dividends

The Company is pleased to declare an interim dividend in respect of the financial period ending 5 October 2022 of $0.0625 per ordinary share, payable on 18 November 2022 to ordinary shareholders on the register as at 21 October 2022. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest, which will result in a reduction in the corporation tax payable by the Company.

The $0.0625 dividend comprises an ordinary dividend of $0.0175 and a special dividend of $0.0450. The Company is currently on track to pay and continues to target a 7 cent. base annual dividend per ordinary share.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 21 October 2022 (the "Election Date").

Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Company's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

Valuation Update

As at 30 September 2022 the unaudited net asset value per Ordinary Share, including current period revenue, was 102.17 cents. The Company's September factsheet will be located on the Company's website, http://bpcruk.com.

As at 5 October 2022 the unaudited net asset value per Ordinary Share, including current period revenue, was 105.47 cents.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24